Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]

Group 1 - The core point of the article highlights significant stock price movements during the week of January 5 to January 9, with 7 stocks increasing over 60% and 13 stocks increasing over 50% [1] - Zhite New Materials topped the weekly gainers with a remarkable increase of 148.84% [1] - Other notable gainers include Shaoyang Hydraulic, Bibet-U, and Kuaiyi Elevator, with weekly increases of 84.91%, 68.89%, and 61.10% respectively [1] Group 2 - On the downside, 7 stocks experienced declines exceeding 15% during the same week [1] - Rongke Technology led the decline with a drop of 26.59% [1] - Other significant decliners included Baihua Pharmaceutical and Tianming Technology, with declines of 21.65% and 19.82% respectively [1]

证券日报网讯 1月9日，百花医药在互动平台回答投资者提问时表示，公司目前经营情况正常，公司将 继续严格按照相关规定，及时履行信息披露义务。 （文章来源：证券日报） ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2026-002 新疆百花村医药集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 新疆百花村医药集团股份有限公司（以下简称"公司"）股票在连续三 个交易日内日收盘价格跌幅偏离值累计达到 20%。根据《上海证券交易所股票上 市规则》（以下简称"上市规则"）的有关规定，属于股票交易异常波动。 经公司自查并向控股股东、实控人核实，公司控股股东、实际控制人筹 划控制权变更事项已终止，详见前期公告，除公司已披露公告之外，不存在应披 露而未披露的重大信息。 截止目前，公司生产经营情况正常。 一、股票交易异常波动的具体情况 公司股票于 2026 年 1 月 7 日、2026 年 1 月 8 日、2026 年 1 月 9 日连续三个 交易日内日收盘价格跌幅偏离值累计达到 20%，根据《上市规则》的有关规定， 属于股票交易异常波动。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，截至目前，公 ...

Core Viewpoint - Baihua Pharmaceutical (600721) experienced a significant drop, reaching the daily limit down, with a trading volume of 262 million yuan and a turnover rate of 6.85% [2] Group 1: Stock Performance - The stock's price fell by 9.91%, leading to its inclusion on the Shanghai Stock Exchange's watch list for significant price deviation [2] - Over the past six months, the stock has appeared on the watch list five times, with an average price drop of 2.37% the day after being listed and an average decline of 4.10% over the following five days [3] Group 2: Trading Activity - The net selling amount from brokerage seats totaled 18.64 million yuan, with the top buying brokerage being Zhongshan Securities, which purchased 4.96 million yuan worth of shares, while the top selling brokerage was China Galaxy Securities, selling 10.19 million yuan [2][3] - The stock saw a net outflow of 74.48 million yuan in principal funds today, with large orders contributing to a net outflow of 58.93 million yuan and 15.55 million yuan from larger orders [3] Group 3: Financial Performance - For the first three quarters of 2025, Baihua Pharmaceutical reported a revenue of 299 million yuan, reflecting a year-on-year growth of 2.74%, and a net profit of 32.67 million yuan, which is a 36.41% increase compared to the previous year [3]

Group 1 - The stock of Baihua Pharmaceutical experienced a significant decline on January 7, closing at 11.02 yuan, with a trading halt observed [1] - The buying side showed a small inflow of funds, with the top buyer being Ping An Securities, which purchased 1.1064 million yuan [1] - The total buying amount from the top five buying seats was 3.6432 million yuan [1] Group 2 - The selling side exhibited a more pronounced outflow, with the main seller being Industrial Securities, which sold 9.918 million yuan [1] - The total selling amount from the top five selling seats reached 20.6823 million yuan, significantly higher than the total buying amount [1] - Notably, the selling activities were associated with funds linked to the so-called "Wenzhou Gang" [1]

Core Viewpoint - Baihua Pharmaceutical (600721) experienced a trading halt today, with a daily decline of 10.02% and a turnover rate of 0.86%, resulting in a transaction volume of 36.36 million yuan [2] Trading Activity - The stock was listed on the Shanghai Stock Exchange due to a daily price deviation of -10.02%, with a total net sell of 17.04 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction volume of 24.33 million yuan, with a buying amount of 3.64 million yuan and a selling amount of 20.68 million yuan, leading to a net sell of 17.04 million yuan [2] - The largest buying brokerage was Ping An Securities, Shenzhen Longhua People's Road, with a purchase amount of 1.11 million yuan, while the largest selling brokerage was Industrial Securities, Shanghai Tianyao Bridge Road, with a selling amount of 9.92 million yuan [2] Capital Flow - The stock saw a net outflow of 27.99 million yuan in principal funds today, with a significant outflow of 21.76 million yuan from large orders and 6.24 million yuan from medium orders [2] - Over the past five days, the total net outflow of principal funds reached 27.99 million yuan [2] Financial Performance - According to the Q3 report released on October 28, 2025, the company achieved a total operating revenue of 299 million yuan in the first three quarters, representing a year-on-year growth of 2.74%, and a net profit of 32.67 million yuan, reflecting a year-on-year increase of 36.41% [2]

百花医药此前发布的《关于筹划控制权变更事项的停牌公告》《关于筹划控制权变更事项继续停牌 的公告》及上述最新公告均未对交易方进行披露。 由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见，本着审慎 的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变更事项不会对 公司经营业绩和财务状况产生重大不利影响。为维护投资者利益，根据相关规定，经公司向上海证券交 易所申请，公司股票于 2026 年 1 月 7 日（星期三）开市起复牌。 中国经济网北京1月7日讯 百花医药(600721.SH)今日复牌跌停，截至收盘报11.02元，跌幅9.97%。 该股停牌前的最后一个交易日（2025年12月26日）盘中最高涨9.00%。 百花医药昨日晚间披露关于终止筹划控制权变更事项暨复牌的公告。因公司控股股东、实际控制人 米在齐、米恩华、杨小玲正在筹划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。鉴于 该事项正在洽谈当中，尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异 常波动，经公司向上海证券交易所申请，公司股票自 2025 年 12 月 29 日（星 ...

百花医药(600721.SH)今日复牌一字板跌停，目前封单金额高达3.24元，现报11.2亿元，总市值42.38亿 元。消息上，百花医药昨日盘后公告，因公司控股股东、实际控制人与交易对方未就控制权变更相关重 大事项达成一致意见，决定终止本次控制权变更事项。业绩方面，2025年前三季度，百花医药营收为 2.986亿元，同比增长2.74%，净利润3267万元，同比增长36.41%。 ...

Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]